I have a broad background in clinical pharmacology with specific training and expertise in anticancer nanoparticles. At the University of North Carolina (UNC), I used mouse models and clinical studies in cancer patients to investigate phenotypic probes of the mononuclear phagocyte system as biomarkers for personalizing therapy with anticancer liposomes. I also investigated the preclinical and clinical pharmacokinetics of novel anticancer nanoparticles such as Stealth liposomal CKD-602 (a camptothecin analogue), Optisomal topotecan, and folate-targeted polyethylene glycol- and gadolinium-PRINT (particle replication in non-wetting template)-nanoparticles.
I joined the School of Pharmacy at TTUHSC as a new tenure-track assistant professor in September 2010 with the long-term goal of establishing a research program which is nationally/internationally recognized in the immuno-pharmacology of nanoparticles. My immediate research focus was on identifying novel immune mechanisms of resistance to anticancer nanoparticles. The overall goal of my research is to understand the consequences of the interactions between nanoparticles and the host immune system in order to develop novel strategies to maximize the efficacy of nanoparticle drugs.